Cytokinetics to Present Key Aficamten Data at HCMS Scientific Sessions

  • Cytokinetics to present three data sets on aficamten at HCMS Scientific Sessions on November 6, 2026, including two late-breaking oral abstracts and one poster presentation.
  • Presentations focus on aficamten's effects in non-obstructive hypertrophic cardiomyopathy (nHCM) and long-term therapy in obstructive HCM (oHCM).
  • Company plans to submit Supplemental New Drug Application for aficamten in nHCM in Q4 2026 following positive Phase 3 trial results.
  • Aficamten is currently approved for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in multiple regions.

Cytokinetics is advancing its lead asset aficamten into new hypertrophic cardiomyopathy indications, potentially expanding its addressable market. The upcoming presentations and planned regulatory submission represent key milestones in the company's strategy to become a leader in cardiac muscle dysfunction therapies. Success in non-obstructive HCM could significantly boost aficamten's commercial potential beyond its current approved indication.

Regulatory Timing
Whether Cytokinetics can secure nHCM approval for aficamten by year-end 2026 as planned.
Market Expansion
How the company positions aficamten in the broader hypertrophic cardiomyopathy market beyond oHCM.
Pipeline Progress
The pace of development for Cytokinetics' other cardiac myosin inhibitors in heart failure indications.